natgillin/translations-raw huggingface dataset:
Other benzyl bromides substituted with optionally substituted phenyl or optionally substituted C5-6 heteroaryl may readily be prepared by the methods of these preparations. 
Ostali supstituenti benzil bromida sa po izboru supstituiranim fenilom ili po izboru supstituiranim Csg heteroarilom mogu biti pripravljeni pomoću postupaka za ova pripravljanja.
Seed of a plant of claim 1 wherein said seed comprises DNA encoding a Cryl Ca insecticidal protein and DNA encoding a Cry1Fa insecticidal protein. 
2. < Sjeme biljke prema zahtjevu 1, naznačeno time, da navedeno sjeme obuhvaća DNK koja kodira insekticidni protein Cry1Ca i DNK koja kodira insekticidni protein Cry 1Fa.
The method of claim 13, wherein the fraction represents at least 0.5% of the human genome. 
Postupak prema zahtjevu 13, naznačen time, da frakcija predstavlja najmanje 0,5% humanog genoma.
The product of claim 8, wherein the glass wool is made of E, C, R or AR (alkali-resistant) glass, and the rock wool is made from basalt, or the mineral fibers comprise more than 96% by weight of silica, or the mineral fibers are ceramic fibers based on at least one oxide, nitride, or carbide of a metal or a semimetal. 
Izolacijski proizvod sukladno zahtjevu 11, naznačen time da se mineralna vuna sastoji od staklenih vlakana, kamenih vlakana, vlakana koja sadrže više od 96% u težini silicijevog dioksida ili keramičkih vlakana na bazi najmanje jednog oksida, nitrida ili karbida metala ili metaloida ili smjese ovih spojeva.
The composition of claim 1, wherein the cysteine residue at position 59 in the IDS amino acid sequence is converted into FGly at a molar ratio of 75% or higher. The composition of claim 1, wherein the IDS contains mannose-6-phosphate in an amount of 2.0 to 4.0 moles per mole of IDS. 
IDS pripravak prema zahtjevu 1, gdje IDS čija je aminokiselinska sekvenca SEQ ID broj: 1 sadrži manozu-6-fosfat u količini od 2.0 do 4.0 mola po molu IDS-a, poželjno u količini od 2.5 do 3.0 mola po molu IDS-a.
Use of a compound according to claim 16 or a composition according to any one of claims 17 to 21 and 24 for the manufacture of a medicament for controlling weight gain. 
Uporaba spoja u skladu s bilo kojim zahtjevom 1 do 11, naznačena time, da se koristi za izradu lijeka za kontrolu dobivanja na težini.
After cooling to 25 °C, the stirring is stopped and the internal pressure is equilibrated with the ambient atmosphere. 
Nakon hlađenja do 25 *C miješanje se prekida, a unutarnji tlak seizjednači s okolišem.
This is advantageous as the windows and doors are preferably mounted in the wall elements 2 as late as possible in order to avoid damage to these parts. 
To je pogodno jer je najpoželjnije prozore i vrata postavljati u zidne elemente 2 što je kasnije moguće kako bi so izbjeglo oštećivanje ovih dijelova.
The method according to claim 4, wherein the component b) is selected among methyl esters of fatty acids of plant oils. 
Metoda u skladu sa patentnim zahtjevom 4, naznačena time da je komponenta označena slovom b) odabrana između metilnih estera masnih kiselina biljnih ulja.
In other words, the prodrug does not appear to possess any intrinsic immunosuppressive activity and must be hydrolyzed to rapamycin in order to exhibit the desired pharmacological effect. 
Drugim riječima, čini se da prolijek ne posjeduje imunosupresivnu aktivnost i mora se hidrolizirati u rapamicin kako bi pokazao željeni farmakološki učinak.
Step (d) is preferably carried out on a phenyl sepharose column, such as a Phenyl-Sepahrose Fast Flow column. 
Korak (d) se poželjno provodi u koloni od fenil sefaroze poput kolone za brzi protok od felin sefaroze.
This was used immediately in the following step. 
Ona je uporabljena neposredno u sljedećem koraku.
determining with the processor mechanism evidence of at least a third user mark in the detected third user marking cell based at least in part upon a degree of brightness similarity between: (a) at least a portion of the electronic image surrounding the indicium bounding the third user marking cell; and (b) at least a portion of the electronic image included inside the indicium bounding the third user marking cell. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što dodatno uključuje: određivanje procesorskim mehanizmom dokaza o u najmanju ruku trećoj korisničkoj oznaci u detektiranoj trećoj ćeliji za korisničku oznaku na temelju u najmanju ruku dijelom stupnja sličnosti svjetline između: (a) u najmanju ruku dijela elektronske slike koji okružuje bilješku koja omeđuje treću ćeliju za korisničku oznaku; i (b) u najmanju ruku dijela elektronske slike koji se nalazi unutar bilješke koja omeđuje treću ćeliju za korisničku oznaku.
The pharmaceutical composition for topical use according to the previous claim 2, containing steroids, hormones, proteins, trophic factors, vitamins, non-steroid anti-inflammatory drugs, chemotherapy drugs for topical use, antibiotics, antiviral agents, local anesthetics, enzymes and/or other proteases. 
Farmaceutski pripravak za upotrebu prema prethodnim patentnim zahtjevima 3 ili 4, koji sadržava steroide, hormone, proteine, tropičke faktore, vitamine, nesteroidne protuupalne lijekove, lijekove za kemoterapiju za topikalnu primjenu, antibiotike, antivirusna sredstva, lokalne anestetike, antikoagulanse i/ili fibrinolitička sredstva, enzime i/ili druge proteaze.
using the presence or degree of such binding as a measure of the presence of nucleosomes containing the DNA base in the body fluid sample, wherein the DNA base is selected from: uracil, inosine, xanthine, hypoxanthine or a modified base. 
(iv) korištenje prisutnosti ili stupnja takvog vezanja kao mjere prisutnosti nukleosoma koji sadrže bazu DNK u uzorku tjelesne tekućine, naznačen time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina.
An (aza)indole derivative represented by the general formula: wherein T represents nitro, cyano or trifluoromethyl; 
[Kem. 1] [image] gdje T predstavlja nitro, cijano ili trifluorometil;
The method of claim 11, wherein the transgenic plant is a dicotyledon. 
Postupak prema zahtjevu 10, naznačen time, da transgenska biljka je dikotiledon ili monokotiledon.
The mouse of claim 4, wherein the non-human constant region gene is a rodent constant region gene. 
Miš u skladu s patentnim zahtjevom 4, naznačen time, da je nehumani gen konstantne regije gen konstantne regije glodavaca.
In one embodiment said antibody according to the invention comprises: a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1 or SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 2 or SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 3 or SEQ ID NO: 11, and 
Protutijelo ili fragment protutijela, koje se specifično veže za humani angiopoietin 2 (ANG-2), naznačeno time, da a) varijabilna domena jakog lanca sadrži područje CDR3 od SEQ ID NO:1, područje CDR2 od SEQ ID NO:21 područje CDR1 od SEQ ID NO:3, i b) varijabilna domena slabog lanca sadrži područje CDR3 od SEQ ID NO:4, područje CDR2 od SEQID NO:5i područje CDR1 od SEQ ID NO:6.
The process of claim 38, wherein the composition is shaped to form an extended release matrix formulation in the form of tablet. 
Postupak prema zahtjevu 27, naznačen time da se u koraku b) sastav oblikuje tako da tvori formulaciju matrice s produljenim otpuštanjem u obliku tablete.
providing a discharge (28) which is situated in the centre with respect to the auxiliary injection line (25), 
- < izvedba ispusta (28) koji se nalazi u središtu s obzirom na pomoćnu injekcijsku liniju (25),
In a preferred embodiment, the present invention provides a fast disintegrating lozenge, chewable, orally dispersible or sublingual tablet comprising sevelamer or its pharmaceutically acceptable salts or derivatives as the active pharmaceutical ingredient, one or more binders with hydrogen bond acceptor groups such as polyvinylpyrrolidone in an amount of from 5% to 30% wt, a diluent providing a pleasant sweet taste and cooling sensation such as mannitol, sorbitol and/or dextrate, a disintegrant such as crospovidone or primogel, one or more flavouring/sweetening agents such as menthol, lemon, sucralose and/or vanilla and a lubricant such as magnesium stearate. 
Brzo topljiva oralno raspadljiva tableta prema bilo kojem od prethodnih zahtjeva, naznačena time da dalje sadrži razrjeđivač koji pruža ugodan sladak okus i osjećaj hlađenja poput manitola, sorbitola i/ili dekstrata, sredstvo za raspadanje poput -krospovidona ili glikolata natrijevog škroba, jedno ili oviše sredstava za aromatizaciju/zaslađivanje poput mentola, limuna, sukraloze i/ili vanilije, sredstvo za klizanje poput talka ili koloidnog silicijevog dioksida i mazivo poput magnezijevog stearata.
Use of a compound of Formula I: 
2. < Upotreba spoja Formule I:
ii) said amino acid sequence has at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NOs: 1 to 22, in which for the purposes of determining the degree of amino acid identity, the amino acid residues that form the CDR sequences (indicated with X in the sequences of SEQ ID NOs: 1 to 22) are disregarded. 
Polipeptid prema bilo kojem od zahtjeva 1-4, naznačen time da sekvenca aminokiseline sadrži polipeptid koji ima barem 80% identičnu aminokiselinu s barem jednom od sekvenci aminokiseline od SEQ ID NO: 623 do 693, u kojoj su u svrhu određivanja stupnja identičnosti aminokiselina, zanemareni ostaci aminokiselina koji tvore CDR sekvence.
The protective helmet according to claim 1, wherein a second coupling member is respectively provided or disposed on the first coupling elements. 
Zaštitna kaciga (2) prema jednom od prethodnih zahtjeva, naznačena time da je drugi spojni član (21) zasebno izveden ili raspoređen na prvim spojnim elementima (7).
and at least a processing unit which is adapted to: 
i najmanje jedinicu za obradu (25) koja je prilagođena da:
the payment processor is configured to receive a payment authorization text message from the mobile phone of the user authorizing or not authorizing the payment of the payment request; 
Sustav prema zahtjevu 1, naznačen time da tekstualna poruka autorizacije plaćanja s mobilnog telefona korisnika (102) uključuje osobni identifikacijski kod jedinstven za korisnika (102).
Exploration was considered to be directing the nose at a distance closer than 2 cm to the object and/or touching the object. 
Istraživanjem objekta se smatra usmjeravanje nosa na udaljenost manju od 2 cm od objekta i/ili dodirivanje objekta.
said acid(s) of step b) each having a pKa of greater than 2.5 and less than or equal to 7, when measured at 20° C., associated with the ionisation of their first available hydrogen, and a corresponding anion formed on loss of this first available hydrogen capable of forming water-soluble calcium salts; 
(i) svaka navedena kiselina ili navedene kiseline iz koraka b) imaju pKa veći od 2.5 1 manji od ili jednak 7, mjereno kod 20*C, povezano sa ionizacijom njihovog prvog dostupnog vodika, te odgovarajući anion formiran na mjestu ovog prvog dostupnog vodika koji je sposoban formirati kalcijeve soli topive u vodi;
More particularly, a crosslinking agent according to the present invention may be preferably selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, an endogenous polyamine, and mixtures thereof. 
(BDDE), 1,4-bis(2,3- epoksipropoksi)butan, = 1,4-bisglicidiloksibutan, = 1,2-bis(2,3-epoksipropoksijetilen, - 1-(2,3-epoksipropil)-2,3- epoksicikloheksan, pustrescin, spermidin, spermin, te njihovu smjesu.
filtration of the gained eluate. 
- filtracije dobivenog eluata.
coupling compound (1) and compound (2) under amide bond-forming conditions and deprotecting the product to form compound (3): 
(a) sprezanje spoja (1) i spoja (2) u uvjetima za nastanak amidne voze te skidanje zaštite, čime se dobiva spoj (3): m").
Device according to Claim 1 or 2, in which the passage (11) is situated outside the area of the panel (3) defined by the columns (12, 13). 
Uređaj u skladu s patentnim zahtjevom | ili 2, naznačen time što je prolaz (11) smješten izvan prostora ploče (3) koji je određen stupovima (12, 13).
contacting off-gas from the pyrolysis and/or gasification steps with an oxidation catalyst external to the chamber to convert carbon monoxide and hydrocarbons in the off-gas into carbon dioxide and water; 
- < dovođenje plina oslobođenog tijekom faze pirolize i/ili uplinjavanja u kontakt s nekim oksidacijskim katalizatorom da bi se ugljični monoksid i hidrokarboni iz oslobođenog plina konvertirali u ugljični dioksid i vodu;
4 of the indole then R8 does not exist; when the sulphur atom is attached via atom nr. 
ako je atom sumpora pričvršćen preko atoma br. 5 indola, tada R* ne postoji
The method of claim 15, wherein the combination of the method of claims 1 to 14 and the one or more other methods is a linear function of these methods or a multiplicative function of these methods. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što je kombiniranje postupka u skladu s patentnim zahtjevima 1 do 10 s jednim ili više drugih postupaka linearna funkcija tih postupaka ili multiplikativna funkcija tih postupaka.
In all embodiments the parts of the base unit 3 are preferably made in a plastics material such as PET or PE. 
U svim izvedbama dijelovi osnovne jedinice 3 su ponajprije izrađeni iz plastičnog materijala kao što je PET ili PE.
The wine decanter device of claim 7, wherein said support means comprise four vertical edges (9) disposed towards the four corners of said base (10). 
Uređaj za pretakanje vina prema patentnom zahtjevu 7, u čemu, spomenuto potporno sredstvo sadrži četiri vertikalna ruba (9) sortiranih prema četiri ugla spomenute baze (10).
Such other active ingredients may be antimicrobial agents, in particular: 
Takvi drugi aktivni sastojci mogu biti protu-bakterijski agensi, posebice:
In another aspect, the compound of Formula (IA) as an anhydrate in crystalline form is characterised by an XRPD pattern comprising the following peaks: 
Spoj prema zahtjevu 1, gdje kristalni oblik spoja je naznačen time što XRPD uzorak sadržava sljedeće pikove:
The camphorsulphonic acid salt of (10 g) was dissolved in a mixture of hot absolute ethanol (170 ml) and methanol (30 ml). 
Sol kamforsulfonske kiseline (10 g) se otopi u smjesi vrućeg apsolutnog etanola (170 ml) 1 metanola (30 ml).
(wherein R1 R2 and R3 have the meanings defined in formula (I) and R6 is 2-hydroxy phenyl) with carbonyl dimidazole or thiocarbonyl diimidazole in a suitable solvent such as dichloromethane and subsequent reaction of the products this formed with the amine HNR4R5. 
(gdje Ri, R, i Rz znače kao što je definirano za formulu (1), a R4 je 2-hidroksifenil) s karbonildiimidazolom ili tiokarbonildiimidazolom, u pogodnom otapalu, poput diklormetana, te naknadnom reakcijom tako dobivenih produkata s aminom HNRRs.
A parenteral formulation for intravenous use, containing 4 mg of active compound per ml, was prepared from the following ingredients: 
Parenteralna formulacija za intravenoznu upotrebu, koja sadrži 4 mg aktivnog spoja na ml, dobivena je od slijedećih komponenata:
a total amount of protein of at least 4% (w/w) a total amount of solids of a denatured whey protein composition of at least 2% (w/w) relative to the total weight of the beverage, the denatured whey protein composition containing: 
ukupnu količinu proteina od najmanje 4 % (tež./tež.) - ukupnu količinu čvrstih tvari u pripravku denaturiranog proteina sirutke od najmanje 2 % (tež./tež.) u odnosu na ukupnu težinu napitka, gdje pripravak denaturiranog proteina sirutke sadrži:
The spreader according to claim 3, wherein the at least one movable plate is configured such that it encloses a cuboid or prism-shaped volume portion of the volume of the spreading-material container in which the liquid tank is housed. 
Uređaj za posipanje u skladu s bilo kojim od patentnih zahtjeva 3 do 5, naznačen time što je najmanje jedna pokretna ploča (21, 22, 23) tako konfigurirana da može obuhvatiti kockasti ili prizmatični dio volumena spremnika materijala za posipanje (3) u kojeg se stavlja spremnik tekućine (10).
10 provides a generalized Scheme 7 for cleaving the sidechain of 9,10-a,a-OH taxane analogs according to the present invention. 
Prema tome, slika 10 daje opću shemu 7 za cijepanje bočnog lanca 9,10-c,a-OH analoga taksana.
The process according to claim 1, wherein the spherical polymer particles have a monomodal particle size distribution. 
Postupak prema zahtjevu 1, naznačen time što sferične polimerne čestice imaju monomodalnu raspodjelu veličine čestica.
Classification/Absorbance Ratio For the purposes of this specification, Absorbance Ratio of a material is defined as the absorbance of an 0.1% (w/v) solution of solids in water at 280 nm divided by the absorbance of the same solution at 560 nm. 
Klasifikacija/Omjer apsorbancije Za svrhe ove specifikacije, omjer apsorbancije materijala se definira kao apsorbancija 0,1%-tne (mas/v) otopine čvrstih tvari u vodi pri 280 nm, podijeljeno s apsorbancijom iste otopine pri 560 nm.
In other embodiments, L is 
X je odsutan, a L je
Na-pyruvate, and/or a protective agent such as Pluronic F68. 
Na-piruvata i/ili zaštitnu tvar poput Pluronic F68.
a sequence of amino acids at least 80% identical to SEQ ID NO:363; 
aminokiseline koje imaju slijed najmanje 80% identičan slijedu SEQ ID NO:363; di.
is the residue of an amino acid after the removal of the hydroxyl moeity from the carboxyl group thereof; 
R* je ostatak aminokiseline nakon uklanjanja hidroksilnog dijela s njezine karboksilne skupine;
Through this process, small particles are formed, so called "seeds", which continue to grow until the desired particle size is reached. 
Tim se postupkom stvaraju male čestice, tzv. «klice» koje se nastavljaju povećavati dok se ne postigne željena veličina.
The transmitter of any of claims 1 to 4, wherein, when a value of the L1 TI mode information is "01", the time interleaving depth is the minimum number of OFDM symbols required for carrying the L1 signaling data. 
Prijenosnik iz bilo kojeg od patentnih zahtjeva 1 do 3, pri čemo postupci umetanja bitova i vremena nisu izvedeni na zaglavlju razine 1.
wherein the recondenser (103) condenses the boil-off gas by using LNG extracted from the LNG tank, directly mixing the LNG and the boil-off gas, 
Sustav dobave pogonskog plina za brod prema zahtjevu 1, naznačen time da se LNG izvlači iz spremnika LNG.
The furnace set forth in claim 1, wherein the heater comprises a heating element and a conveyor that conveys batch material through the heater toward an outlet of the heater, wherein the outlet of the heater is positioned below a top of the dam wall. 
grijač (20, 46, 57) za uvođenje djelomično rastaljene smjese materijala u komoru za taljenje u peći; i izlazni otvor (21) za grijač, koji je smješten ispod vrha pregradnog zida.
According to a more preferred embodiment of the invention, the nucleic acid molecule is surrounded by the homologous sequences in the vector. 
Vektor prema patentnom zahtjevu 5, naznačen time da je rečena molekula nukleinske kiseline okružena rečenom homolognom sekvencijom.
Suitable bases for the steps include, for example, triethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane, and 1,8-diazabicyclo[5,4,0]undec-7-ene, or mixtures of 2 or more thereof. Suitable solvent for crystallization includes hydrocarbon, alcohols, ethers, ketones, esters, xylene, N-methylpyrrolidinone. 
Postupak u skladu s patentnim zahtjevom 36, wherein saidprvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.O0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.O0]undec-7-en; te smjese 2 ili višo njih.
The container 1100 includes at least one wall 1101 that defines a fluid containing area. 
Posuda 1100 uključuje najmanje jednu stijenku 1101 koja određuje prostor za zaprimanje tekućine.
A process according to claim 1 comprising electrochemically generating (I+) cations and, then, contacting them with the selected compound of formula (1), as defined in claim 1. 
Postupak prema zahtjevu 8 naznačen time da se dobivena otopina iz koraka (a) prebacuje u odvojeni reaktor i dovodi u kontakt sa spojem s formulom (1) ili s njegovom otopinom.
R3-R6 are as defined in any one of claims 13-20; 
- > RŽ-RĆ su kako je definirano u jednom od zahtjeva 13-20
The use of the invention is therefore as follows: with reference to the attached drawings, the buttress element 5 is connected to the sole 2 and to the shell 3 providing the second appendix 20 and the third appendix 23 respectively in the first seat 9 and in the cavity 13, and contemporarily positioning the walls 16a and 16b inside the wings 7a and 7b of the shell 3. 
Izum se stoga može upotrijebiti kako slijedi: s pozivom na priložene crteže, potporni element 5 se spoji s potplatom 2 1 s plaštem 3 osiguravajući drugi nastavak 20 i treći nastavak 23 u prvom dosjedu 9 i u gnijezdu 13, a privremeno se namjeste stijenke 16a 1 16b unutar krila 7a i 7b plašta 3.
To a stirred dispersion of 2-chloro-4-methanesulfonyl-benzaldehyde (25 g, 0.11 mol) in absolute ethanol (120 ml) is added sodium borohydride (4.6 g, 0.12 mol) whilst cooling with an ice-bath to maintain room temperature. 
U miješanu disperziju 2-klor-4-metansulfonil-benz-aldehida (25 g, 0,11 mola) u apsolutnom etanolu (120 ml) doda se natrijev borhidrid (4,6 g, 0,12 mola) uz hlađenje s ledenom kupelji da se održi na sobnoj temperaturi.
An expression vector comprising the nucleic acid molecule of claim 9. 
Ekspresijski vektor naznačen time da sadrži molekulu nukleinske kiseline prema zahtjevu13.
An antisense oligonucleotide according to clause 15 selected from SEQ ID NOS: 173, 175, 179, 180, 187, 188, 203, and 169, optionally wherein the uracil bases (U) are thymine bases (T). 
Antisens oligonukleotid, naznačen time što se veže na ljudski distrofinski gen radi indukcije zaobilaženja egzona u distrofinskom genu, sa slijedom SEQ ID NO: 181, gdje su izborno uracilne baze (U) timinske baze (T).
in a solution with an initial glycosaminoglycan concentration of 10(±1)% to 20(±2)% w/v; 
(ii) uotopini s početnom koncentracijom glikozaminoglikana od 10(+1)% do 20(+2)% mas/v;
The antibody or fragment according to claim 7, wherein the antibody is a fully human antibody, chimeric antibody, humanized or primatized antibody; Fab, Fab', F(ab')2, F(ab'), F(ab), Fv or scFv fragment and minimal recognition unit. 
Protutijelo ili fragment protutijela prema zahtjevu 1 za uporabu u terapiji ili protutijelo ili fragment protutijela prema zahtjevu 2 za uporabu za liječenje raka, naznačeno time što je navedeno protutijelo ili fragment protutijela vezan za enzim, toksin, terapeutsko sredstvo, ili kemoterapijsko sredstvo.
Likewise preferably, said sugar polyol is an agent selected from the group consisting of mannitol and/or sorbitol. Among these, mannitol is a particularly preferred sugar polyol. 
Formulacija prema zahtjevu 6 ili 7, naznačena time, da je navedeni šećerni poliol takvo sredstvo koje je odabrano iz skupine koja se sastoji od manitola i/ili sorbitola.
for compounds of formula I wherein W is -[CRxRy]m-, reaction of a compound of formula IX, wherein L6 represents a suitable leaving group and A1 to A5 and X are as defined in Claim 1, with a compound of formula X, H2N-W-D X wherein W and D are as defined in Claim 1; and 
za spojeve s formulom I pri čemu W je -[CRxRy]m-, reakcijom spoja s formulom IX, [image] pri čemu L6 predstavlja prikladnu izlaznu skupinu i A1 do A5 i X su kako je definirano u zahtjevu 1, sa spojem s formulom X,
A process according to claim 21, wherein the step (f) comprises crystallisation using a toluene and isohexane solvent system. A process for the manufacture of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, ZD6474: from a compound of the Formula X: which process comprises the steps of: 
Postupak prema zahtjevu 21, naznačen time, da korak (f) obuhvaća kristalizaciju pomoću sustava otapala sa toluenom i izoheksanom. HR P20100019T 23. Postupak za proizvodnju 4-(4-bromo-2-fluoroanilino)-6-metoksi-7-(1-metilpiperidin-4-ilmetoksi)kinazolina, ZD6474:
Psychotic delusions can be classified into primary and secondary types. 
Psihotične iluzije se mogu klasificirati u primarni i sekundarni tip.